All In Biotech

Drug Trial Radar · NCT07916480

Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis

A Phase 3, 52-Week Study of Once-Daily Roflumilast Cream 0.3% in Participants With Moderate to Severe Atopic Dermatitis, Including a 4-Week Double-Blind, Vehicle-Controlled Phase Followed by a 48-Week Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 415 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

415

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Apr 27, 2028

Study completion Mar 28, 2029

Sponsor

Lead sponsor
Arcutis Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis. Approximately 415 participants will be randomized in a 2:1 ratio to receive roflumilast cream 0.3% or matching vehicle cream during a 4-week double-blind, vehicle-controlled treatment period. Following completion of the double-blind treatment period, all participants will enter a 48-week open-label extension and receive roflumilast cream 0.3%. The study will assess the efficacy of roflumilast cream 0.3% in improving signs and symptoms of atopic dermatitis and evaluate its long-term safety and tolerability through Week 52.

Conditions

  • Atopic Dermatitis
  • Atopic Dermatitis (AD)
  • Atopic Dermatitis (Eczema)

Interventions

  • Roflumilast Cream 0.3%Drug

    Roflumilast cream 0.3% administered topically once daily to affected areas during the 4-week double-blind treatment period. Participants may continue treatment with roflumilast cream 0.3% during the 48-week open-label extension.

  • Vehicle CreamDrug

    Matching vehicle cream administered topically once daily to affected areas during the 4-week double-blind treatment period. Participants will receive roflumilast cream 0.3% during the open-label extension phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement of vIGA-AD Success at Week 4Time frame: Week 4

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Arcutis Site 324

    Birmingham, Alabama · Recruiting

  • Arcutis Site 337

    Bryant, Arkansas · Recruiting

  • Arcutis Site 321

    Miami Lakes, Florida · Recruiting

  • Arcutis Site 320

    Chicago, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.